Clinical supply planning starts with assumptions, not sales history. See how enrollment, SKUs, approvals, shelf life, yield, inventory, and CDMOs shape the plan.
- Root Causes, Part 3: The Hidden Cost of Clinical Supply Work That Doesn't Move Trials Forward
- The Silent Stockout: No One Owns The Data That Would Have Caught It
- Token Costs Will Decide Clinical Supply AI
- What Is "Demand" When There Are No Sales?
- The Reliance Trap: When Regulatory Strategy Becomes A Clinical Supply Problem
- Clinical Trial Supply Chains Are Entering The Era Of Predictive Risk Management
- Root Causes, Part 2: The Translation Problem Behind Clinical Trial Execution
- CSM Feasibility Begins With Research Strategy And Study Design
ON-DEMAND WEBINARS
Investigational products present a distinctly high-risk environment for labeling and barcoding. Explore best practices for barcoding solutions that allow for improved medication safety in clinical trials.
If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.
Explore best practices for comparator selection and supply optimization in clinical trials, including sourcing strategies, risk mitigation, regulatory compliance, and real-world cost-saving case studies.
This webinar will offer best practices for UAT for sponsor organizations with the aim of changing the conversations and expectations around the UAT process.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![small-mole-cdmo-GettyImages-1465073057]( "Breaking Down Early Small Molecule Development")
Breaking Down Early Small Molecule DevelopmentAdopt an integrated development strategy to streamline the path from early development to the clinic, ensuring timely clinical supply while reducing delays, risk, and inefficiencies.
-
![GettyImages-836663414 medical team meeting]( "Sponsor Overcomes Hold And Steers Products Through Development")
Sponsor Overcomes Hold And Steers Products Through DevelopmentUncover how a small-sized biotech company was able to resolve critical regulatory CMC deficiencies to meet FDA requirements.
-
![GettyImages-1163506017 labeling]( "IMP Labeling: EU CTR Transition Considerations")
IMP Labeling: EU CTR Transition ConsiderationsReview current requirements as outlined by the EU Clinical Trial Regulation, supporting guidance, and three key considerations when planning IMP labeling activities for ongoing studies.
-
![Laptop clinical trials iStock-653839742]( "What Are Decentralized Clinical Trials (DCTs)?")
What Are Decentralized Clinical Trials (DCTs)?Discover how DCTs leverage “virtual” tools, such as telemedicine, sensory-based technologies, wearable medical devices, and direct delivery of study drugs and materials to patients’ homes.
-
![Scientist research laboratory pipette GettyImages-487041629]( "Overcoming The Complex Logistics Of Autologous Cell Therapy Trials: A Deep Dive Into Challenges And Solutions")
Overcoming The Complex Logistics Of Autologous Cell Therapy Trials: A Deep Dive Into Challenges And SolutionsExplore critical logistical requirements in autologous cell therapies logistics and learn how to overcome challenges and achieve successful and timely autologous cell therapy trials.
-
![GettyImages-1070902452-planning-tracking-packaging-shipment]( "Winning The Race To FPI With Early Randomization And Trial Supply Management")
Winning The Race To FPI With Early Randomization And Trial Supply ManagementLearn why the ability to get investigational products to sites, and appropriately store them, is not a given – and this oversight can have serious consequences.
-
![iStock-1088247762-risk]( "Avoiding The Risk Of A Non-Transparent Clinical Supply Solution")
Avoiding The Risk Of A Non-Transparent Clinical Supply SolutionWith the supply chain and transportation logistics disruption caused by the COVID-19 pandemic, full documentation and complete transparency becomes even more important to avoid delays and assert provenance.
-
![Risk Management-GettyImages-665231256]( "Flexible Integrations To Reduce Risks And Increase Efficiencies")
Flexible Integrations To Reduce Risks And Increase EfficienciesLearn how a trial team kept the blind of central lab samples and patient treatment across a Phase III and extension trial, whilst optimizing the supply chain.
-
![accuracy-in-drug-development-GettyImages-2249698250]( "GMP Clinical Storage Strategies for Today's Complex Trials")
GMP Clinical Storage Strategies for Today's Complex TrialsTemperature‑sensitive therapies need more than basic freezer space. Purpose‑built GMP storage protects product integrity, supports compliance, and adds flexibility as trial complexity grows.
-
![GettyImages-1184502868 oncology patient]( "Emerging Biopharm Rapidly Sets Up Phase 1 Oncology Trial")
Emerging Biopharm Rapidly Sets Up Phase 1 Oncology TrialUncover how an emerging biopharmaceutical company was able to expedite the initiation of a Phase 1 oncology trial for a novel treatment targeting relapsed/refractory multiple myeloma.
- Root Causes, Part 3: The Hidden Cost of Clinical Supply Work That Doesn't Move Trials Forward
- Root Causes, Part 2: The Translation Problem Behind Clinical Trial Execution
- Root Causes, Part 1: When Trial Design Locks In Supply Risk
- Expanded Expertise, Deeper Insight: Clinical Supply Leader Welcomes Two New Advisors
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.
